{"Soft-tissue": [0], "sarcomas": [1], "represent": [2], "a": [3, 152, 162, 212, 231], "heterogeneous": [4], "group": [5, 147, 213], "of": [6, 17, 52, 63, 66, 91, 105, 135, 183, 204, 208, 214, 219], "cancer,": [7], "with": [8, 19, 159, 176, 216], "more": [9], "than": [10], "50": [11], "histological": [12], "subtypes1,2.": [13], "The": [14, 145], "clinical": [15, 39, 165, 190], "presentation": [16], "patients": [18, 175, 215], "different": [20], "subtypes": [21, 51, 173], "is": [22], "often": [23], "atypical,": [24], "and": [25, 70, 77, 81, 83, 113, 117, 142, 151, 179, 192, 222, 230], "responses": [26], "to": [27, 156, 188, 235], "therapies": [28], "such": [29], "as": [30], "immune": [31, 172, 236], "checkpoint": [32, 237], "blockade": [33, 158, 238], "vary": [34], "widely3,4.": [35], "To": [36], "explain": [37], "this": [38, 168], "variability,": [40], "here": [41], "we": [42], "study": [43], "gene": [44], "expression": [45], "profiles": [46], "in": [47, 121, 132, 161, 174, 199], "608": [48], "tumours": [49], "across": [50], "soft-tissue": [53, 177, 209], "sarcoma.": [54], "We": [55], "establish": [56], "an": [57, 92], "immune-based": [58], "classification": [59], "on": [60], "the": [61, 64, 67, 103, 127, 133, 171, 181, 205], "basis": [62], "composition": [65], "tumour": [68, 206], "microenvironment": [69, 207], "identify": [71], "five": [72], "distinct": [73], "phenotypes:": [74], "immune-low": [75], "(A": [76], "B),": [78], "immune-high": [79], "(D": [80], "E),": [82], "highly": [84], "vascularized": [85], "(C)": [86], "groups.": [87], "In": [88], "situ": [89], "analysis": [90], "independent": [93], "validation": [94], "cohort": [95], "shows": [96], "that": [97, 109, 226], "class": [98], "E": [99], "was": [100], "characterized": [101], "by": [102], "presence": [104], "tertiary": [106, 185, 223], "lymphoid": [107, 186, 224], "structures": [108, 187, 225], "contain": [110], "T": [111, 140], "cells": [112, 116, 125, 141], "follicular": [114], "dendritic": [115], "are": [118, 126], "particularly": [119], "rich": [120], "B": [122, 124], "cells.": [123], "strongest": [128], "prognostic": [129], "factor": [130], "even": [131], "context": [134], "high": [136, 153, 217, 232], "or": [137], "low": [138], "CD8+": [139], "cytotoxic": [143], "contents.": [144], "class-E": [146], "demonstrated": [148], "improved": [149, 228], "survival": [150, 229], "response": [154, 233], "rate": [155, 234], "PD1": [157], "pembrolizumab": [160], "phase": [163], "2": [164], "trial.": [166], "Together,": [167], "work": [169], "confirms": [170], "sarcoma,": [178], "unravels": [180], "potential": [182], "B-cell-rich": [184], "guide": [189], "decision-making": [191], "treatments,": [193], "which": [194], "could": [195], "have": [196, 227], "broader": [197], "applications": [198], "other": [200], "diseases.": [201], "Immune": [202], "profiling": [203], "sarcoma": [210], "identifies": [211], "levels": [218], "B-cell": [220], "infiltration": [221], "therapy.": [239]}